|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Shattuck Labs, Inc. (STTK) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
41,740,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Shattuck Labs is a clinical-stage biopharmaceutical company engaged in developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint and GADLEN™ platforms, as classes of biologic medicines capable of multifunctional activity with applications in oncology and inflammatory diseases. Co.'s product candidate SL-172154, which is in Phase 1 clinical trial for the treatment of patients with ovarian cancer. Co.'s second product candidate, SL-279252, which is developed to inhibit the PD-1/PD-L1 interaction and activate the OX40 costimulatory receptor and is in Phase 1 clinical trial in patients with solid tumors and lymphoma. Co. has several compounds in preclinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
16,004 |
41,004 |
41,004 |
41,004 |
| Total Sell Value |
$168,522 |
$418,522 |
$418,522 |
$418,522 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
2 |
2 |
2 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thomson Erin Ator |
General CounselOfficer |
• – – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
103,211 |
|
- |
|
| Pandite Arundathy N. |
Chief Medical OfficerOfficer |
• – – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100,303 |
|
- |
|
| Hornblower Josiah |
ChairmanOfficer |
• • • |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,253,750 |
|
- |
|
| Neill Andrew R |
See RemarksOfficer |
• – – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
88,466 |
|
- |
|
| Schreiber Taylor |
Chief Executive OfficerOfficer |
• • – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,705,750 |
|
- |
|
| Gibson Neil W |
Director |
– • – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
52,745 |
|
- |
|
| Brous Tyler |
Director |
– • – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
52,745 |
|
- |
|
| Brous Tyler |
Director |
– • – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,825 |
|
- |
|
133 Records found
|
|
Page 6 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
